

UCLA School of Law
**Center on Reproductive Health,
Law, and Policy**

Immediate Release

June 30th, 2025

Media Contact

Kelsey Padilla

padilla@law.ucla.edu

310-267-4382

**UCLA Law's Center on Reproductive Health, Law, and Policy (CRHLP)
Releases New Resource to Track Legal and Federal Actions That Could
Shape the Future of Mifepristone Access**

Today, the Center on Reproductive Health, Law, and Policy at UCLA Law launched a new resource to monitor ongoing legal and federal regulatory developments that could affect access to mifepristone, a safe and effective medication used in abortion care. The [Mifepristone Litigation and Federal Action Tracker](#) features two regularly updated legal trackers, one focused on litigation and the other on federal administrative action, in a single, comprehensive resource.

The Mifepristone Litigation Tracker provides timely updates and analysis on legal challenges that could impact access to mifepristone nationwide and potentially put medication abortion back in front of the U.S. Supreme Court.

A year after the U.S. Supreme Court held the plaintiffs in *Alliance for Hippocratic Medicine, et al., v. FDA* lacked standing to challenge FDA's regulatory decisions related to mifepristone, related and distinct legal challenges to FDA's approval and regulation of mifepristone remain active across the country. Despite mifepristone's decades-long overwhelming record of safety and effectiveness it is regulated far more heavily than drugs with comparable safety profiles, and abortion ban states and anti-abortion activists are demanding FDA institute even more restrictions on mifepristone. At the same time, health care providers and advocates, as well as states that protect the right to abortion, are asking FDA to remove requirements that create unnecessary barriers to access. Our tracking and analysis breaks down the different types of legal claims raised in pending cases (8 currently), what's at stake, and their status in the courts.

The Mifepristone Federal Action Tracker additionally monitors new federal agency activity starting from January 1, 2025, including FDA actions that may affect how the drug is regulated, prescribed, dispensed, and accessed.

As anti-abortion groups continue to push for nationwide restrictions and advocates work to protect and expand access, these trackers offer clear, current, and credible information on legal developments that could impact access to medication abortion nationwide.

The Center will continue to update these resources as current and new cases progress, and administrative actions unfold.

To explore the Mifepristone Litigation and Federal Action Tracker, visit:

<https://bit.ly/CRHLPmifeTracker>.

XXX

The Center on Reproductive Health, Law, and Policy at UCLA Law is an independently-funded think tank and research center developing long-term, lasting solutions that advance all aspects of reproductive justice and address the current national crisis of abortion access. We are lawyers, policy experts, scholars, and researchers who are working to increase access to abortion and contraception, end racial and economic disparities in maternal health outcomes, support people who decide to build families, and dismantle the gender bias that limits reproductive justice.